Upstream Bio (NASDAQ:UPB) Lowered to "Strong Sell" Rating by Wall Street Zen

Key Points

• Wall Street Zen downgraded Upstream Bio to “Strong Sell” from “Sell,” adding to cautious sentiment around the clinical-stage biotech.
• Analyst views remain mixed: four rate the stock a Buy, two Hold, and one Sell, producing a consensus “Hold” rating and an average price target of $29.67. Recent targets range from $9 at JPMorgan to $36 at HC Wainwright.
• Upstream Bio shares opened at $7.07, near the lower end of their 52-week range, while the company continues to report losses despite slightly exceeding quarterly EPS and revenue estimates.

Upstream Bio (NASDAQ:UPB - Get Free Report) was downgraded by equities research analysts at Wall Street Zen from a "sell" rating to a "strong sell" rating in a report released on Saturday.

Other equities research analysts have also issued reports about the stock. Truist Financial dropped their target price on shares of Upstream Bio to $25.00 and set a "buy" rating for the company in a research report on Tuesday. HC Wainwright began coverage on shares of Upstream Bio in a report on Wednesday, June 3rd. They issued a "buy" rating and a $36.00 price target on the stock. Mizuho lowered their price objective on shares of Upstream Bio from $51.00 to $50.00 and set an "outperform" rating on the stock in a research report on Thursday, May 14th. Weiss Ratings reaffirmed a "sell (e+)" rating on shares of Upstream Bio in a report on Monday, August 3rd. Finally, JPMorgan Chase & Co. lifted their price objective on shares of Upstream Bio from $8.00 to $9.00 and gave the stock a "neutral" rating in a report on Friday. Four investment analysts have rated the stock with a Buy rating, two have issued a Hold rating and one has given a Sell rating to the company's stock. Based on data from MarketBeat.com, Upstream Bio has an average rating of "Hold" and a consensus target price of $29.67.

Upstream Bio Stock Up 2.3%

NASDAQ:UPB opened at $7.07 on Friday. The stock has a market cap of $387.22 million, a P/E ratio of -2.44 and a beta of 1.26. The business's 50-day moving average price is $6.81 and its two-hundred day moving average price is $9.90. Upstream Bio has a twelve month low of $5.85 and a twelve month high of $33.68.

Upstream Bio (NASDAQ:UPB - Get Free Report) last issued its quarterly earnings data on Tuesday, August 11th. The company reported ($0.73) EPS for the quarter, topping the consensus estimate of ($0.74) by $0.01. The company had revenue of $0.77 million during the quarter, compared to analyst estimates of $0.56 million. Upstream Bio had a negative return on equity of 48.40% and a negative net margin of 4,955.67%. On average, equities research analysts expect that Upstream Bio will post -2.87 EPS for the current fiscal year.

Hedge Funds Weigh In On Upstream Bio

Several institutional investors and hedge funds have recently bought and sold shares of UPB. GF Fund Management CO. LTD. purchased a new position in Upstream Bio in the 4th quarter worth approximately $29,000. Torren Management LLC purchased a new stake in shares of Upstream Bio during the fourth quarter valued at approximately $30,000. Persistent Asset Partners Ltd purchased a new stake in shares of Upstream Bio during the second quarter valued at approximately $34,000. BNP Paribas Financial Markets grew its holdings in shares of Upstream Bio by 229.8% in the second quarter. BNP Paribas Financial Markets now owns 3,097 shares of the company's stock worth $34,000 after purchasing an additional 2,158 shares during the last quarter. Finally, Legal & General Group Plc grew its holdings in shares of Upstream Bio by 83.0% in the second quarter. Legal & General Group Plc now owns 3,174 shares of the company's stock worth $35,000 after purchasing an additional 1,440 shares during the last quarter.

Key Upstream Bio News

Here are the key news stories impacting Upstream Bio this week:

• Positive Sentiment: JPMorgan raised its price target for Upstream Bio (UPB) from $8 to $9 while maintaining a “Neutral” rating. The revised target implies approximately 27.3% upside from the referenced share price, providing a modest positive catalyst despite the unchanged cautious rating. Benzinga article
• Positive Sentiment: HC Wainwright retained its “Buy” rating and $36 price target, indicating substantial potential upside if Upstream Bio’s pipeline and development plans progress successfully. MarketBeat analyst coverage
• Neutral Sentiment: HC Wainwright’s revised forecasts continue to project losses, including estimated 2026 earnings of negative $3.09 per share and negative $0.79 and $0.82 per share for the third and fourth quarters, respectively. The firm’s “Buy” rating remains unchanged, but the estimates point to a lengthy path toward profitability.
• Negative Sentiment: HC Wainwright lowered its EPS forecasts across 2026–2030: 2027 to negative $3.31 from negative $3.09, 2028 to negative $3.13 from negative $2.92, 2029 to negative $3.56 from negative $3.35, and 2030 to negative $3.84 from negative $3.42. These broader expected losses may weigh on investor sentiment and offset the benefit of JPMorgan’s target increase. MarketBeat analyst estimates

Upstream Bio Company Profile

Upstream Bio, Inc is a clinical-stage biotechnology company focused on the development of next-generation prophylactic vaccines and immuno-oncology therapies. Leveraging a proprietary viral vector platform, the company aims to deliver optimized antigen payloads that stimulate robust and durable immune responses against both infectious diseases and cancer targets. Upstream Bio's approach emphasizes safety, manufacturability and potential for rapid scale-up to address emerging public health challenges.

The company's research and development pipeline includes multiple viral vector-based candidates in early clinical and preclinical stages.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source